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404Transplantation of puriﬁed CD34þ cells in the
treatment of critical limb ischemia
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Background: This study investigated the feasibility, safety, and efﬁcacy of the intramuscular injection of CD34D cells isolated
from peripheral blood mononuclear cells (PB-MNCs) mobilized by granulocyte colony-stimulating factor (G-CSF) for the
management of patients with critical limb ischemia (CLI) who were considered unlikely to have successful long-term revas-
cularization with open bypass or endovascular methods. Cell therapy represents a new treatment modality for this subgroup of
patients with CLI. To date, bone marrow or PB-MNCs have usually been used for transplantation. The current pilot study
investigated whether the transplantation of puriﬁed CD34D cells only would be competent in ischemia relief and limb salvage.
Methods: FromMay 2009 to July 2011, 25 patients (mean age, 44 ± 12 years) were enrolled, and 25 lower extremities and
three upper extremities were treated. After subcutaneous administration of G-CSF for 5 days at a dose of 5 to 10 mg/kg,
apheresis and immunomagnetic separation were performed to acquire the isolated CD34D cells, which were then
intramuscularly injected into the ischemic sites. The patients were divided into three groups: low-dose, 105/kg; medium-
dose, 5 3 105/kg; and high-dose, 106/kg. The overall outcomes among all patients and the comparison among the
groups were evaluated.
Results: During the follow-up of 6 to 33 months, the overall outcomes showed that the Wong-Baker FACES pain rating
scale score (WFPRSS) decreased from 7 ± 2 to 3 ± 3 (P < .001) and 1 ± 2 (P < .001) at 1 and 2 months, respectively; at 3
and 6 months, respectively, the peak pain-free walking time increased from 4 ± 3 to 13 ± 7 (P < .001) and 18 ± 6 minutes
(P < .001), the ankle-brachial index increased from 0.46 ± 0.21 to 0.60 ± 0.17 (P[ .003) and 0.67 ± 0.15 (P[ .001),
and the transcutaneous partial oxygen pressure increased from 27 ± 10 to 41 ± 11 (P < .001) and 55 ± 12 mm Hg (P <
.001). Ulcers were healed in 10 of the 14 patients; four patients required above-knee or below-knee amputation # 3
months. The Kaplan-Meier estimate of the rate of freedom from major amputation at 6 months was 84% (95% conﬁdence
interval, 63%-94%). The comparison among the three groups (low-dose, 5; medium-dose, 11; high-dose, 9) revealed no
signiﬁcant difference, except that the WFPRSS improvement at 1 month from baseline in the high-dose group (6.3 ± 1.7)
was signiﬁcantly superior to that in the low-dose (3.2 ± 3.3; P[ .0487) and medium-dose (3.7 ± 2.8; P[ .0352) groups.
Conclusions: Transplantation of CD34D cells isolated from G-CSF-mobilized PB-MNCs appears to be feasible and safe,
showing encouraging outcomes in the treatment of CLI patients who appear to have compromised options for long-term
revascularization. (J Vasc Surg 2013;58:404-11.)Critical limb ischemia (CLI) represents one of the most
common vascular diseases, with a prevalence of 220 new
cases every year per 1 million population, conferring a prog-
nosis of high risk for extremity loss and even death.1
Surgical bypass and endovascular revascularization are the
current mainstream treatment modalities for limb salvage.
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#6 months, and nearly 20% will die.2,3 Even in the
subgroup with thromboangiitis obliterans (TAO), which
is considered to have a lower amputation rate in the setting
of complete smoking cessation, the incidence of major
amputation reached 12% in the overall patient population
and up to 19% among those who continued smoking.4
Therapeutic angiogenesis provides a new alternative for
these patients. Previously, most clinical studies in this regard
used bone marrow mononuclear cells (BM-MNCs),5-8
peripheral blood MNCs (PB-MNCs),9 or genes and cyto-
kines.10-13 The present pilot study was initiated to evaluate
the feasibility, safety, and efﬁcacy of the intramuscular trans-
plantation of fresh CD34þ cells immunomagnetically iso-
lated from PB-MNCs; these cells are considered the
predominant functional cells for vasculogenesis.14-16
METHODS
The treatment protocol for this study was approved by
the Ethics Committee of Zhongshan Hospital afﬁliated
with Fudan University. All candidates signed the informed
consent before enrollment.
Inclusion and exclusion criteria and grouping.
Inclusion criteria: (1) men or women aged 21 to 80 years;
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obliterans (ASO), or arteritis caused by other etiologies
such as collagen diseases; (4) surgical or endovascular
procedures were considered unlikely to have successful
long-term revascularization or had failed; (5) >3 months
of medical treatment for CLI, including the use of cil-
ostazol and antiplatelet agents in addition to lipid-lowering
therapy in those with hyperlipidemia; and (6) if present,
a nonhealing ulcer after >4 weeks of optimal care by
a wound care physician and a nurse. Each patient was
required to meet all of these criteria. Exclusion criteria were
(1) #3 months of an acute myocardial infarction and (2)
any contraindication for the administration of granulocyte
colony-stimulating factor (G-CSF).
Patients were recruited throughout China and divided
into three groups according to the different doses of the
low-dose, medium-dose, and high-dose groups, with the
total number of injected cells of 105/kg, 5  105/kg,
and 106/kg, respectively. At least ﬁve patients were antici-
pated for each group. Because the current study was a pilot
study and all of the expected participants had CLI with very
predictable limb loss if revascularization was unsuccessful,
a placebo control group was not included. In participants
with bilateral lesions, cells were only intramuscularly
injected into the limb with CLI, whereas the contralateral
limb with mild ischemia was not injected.
Mobilization, apheresis, isolation, and transplant-
ation. G-CSF and enoxaparin sodium were subcutaneously
administered for 5 days, at the doses of 5 to 10 mg/kg and
1 mg/kg per day, respectively. G-CSF administration was
discontinued in patients in whom the white blood cell
count (WBC) was elevated >60  109/L. Apheresis
(COM.TEC; Fresenius Hemocare, Friedberg, Germany)
and subsequent isolation via immunomagnetic separation
(CliniMACS instrument and CD34 reagent; Miltenyi Bio-
tec, Bergisch Gladbach, Germany) were performed on day
5. Apheresis and puriﬁed products were tested for WBC
and CD34þ cell counts.
Cell transplantation was performed by intramuscular
injection with the patient under spinal anesthesia (for the
lower extremities) or general anesthesia (for the upper
extremities). A total of 80 sites were each injected with
0.5 mL. In participants with arterial occlusions above the
ankle or wrist, the injection was distributed into the calf
and foot or forearm and hand. In those with lesions below
the ankle or wrist, the injection was administered only in
the foot or the hand. Postoperatively, all candidates
received 100 mg aspirin and 100 to 200 mg cilostazol
orally per day for at least 6 months.
End points. Safety end points included any adverse
event from mobilization, apheresis, or injection through
30 days after transplantation, pathogenic angiogenesis in
the retina, and the WBC count during the ﬁrst 3 months.
An ophthalmologist performed a baseline pretransplant
examination of the retina, and the image was acquired
for future comparison with results obtained during the
follow-up imaging. Pathologic retinal angiogenesis was
deﬁned as apparent capillary proliferation on the eyegroundafter transplantation compared with the baseline. Efﬁcacy
end points included the rate of freedom from major
amputations at 6 months, peak pain-free walking time
(PPFWT) on a treadmill at 2.5 km/h and a 10% incline,
the Wong-Baker FACES pain rating scale score (WFPRSS),
the ankle-brachial index (ABI), transcutaneous partial
oxygen pressure (TcPO2), and ulcer healing. Overall
outcomes among all participants and comparison among
the three groups were evaluated.
Follow-up protocol. All patients were monitored
postoperatively once a month during the ﬁrst 3 months,
every 2 months for 4 to 12 months, and every 6 months
thereafter. In addition, a follow-up phone call was placed
every week during the ﬁrst month to determine when the
rest pain began to abate (deﬁned as the time to pain relief)
and for information on use of pain medications.
Statistical analysis. The Kaplan-Meier method was
used to estimate the rate of freedom from major amputa-
tions at 6 months, and the Greenwood method was used
for the corresponding 95% conﬁdence interval (CI). The
ABI, TcPO2, PPFWT, and WFPRSS were expressed as the
mean 6 standard deviation and analyzed via a t-test. A
value of P < .05 was considered a statistically signiﬁcant
difference. The analysis was completed with STATA 8.0
software (StataCorp LP, College Station, Tex).
RESULTS
Patient demographics. From May 2009 to July 2011,
25 patients (24 men, 1 woman) with a mean age of 44 6
12 years (range, 23-75 years) were enrolled. Technical
success was achieved in all patients. Their detailed demo-
graphics are reported in Table I. Of the 25 patients, 18
had TAO, 3 had ASO, and 4 had arteritis caused by
systemic lupus erythematosus, Crohn disease, or nodular
erythema. The diagnosis of TAO was made on the basis of
the Olin criteria.17 Although the occluded segments were
located at the superﬁcial or popliteal artery, or both, in
patients 2, 3, 4, 5, 6, 8, 9, 12, 13, 22, and 24, which
appeared to be inconsistent with the typical clinical features
of TAO, the patients were generally young and free from
atherosclerotic risk factors other than smoking, and the
presence of autoimmune diseases, hypercoagulable states,
diabetes mellitus, popliteal artery entrapment syndrome,
and a proximal source of emboli had been excluded. In
addition, superﬁcial thrombophlebitis coexisted in eight
patients, which represented one of the major features
differentiating TAO from most other vasculitides and
atherosclerosis.
A total of 25 lower extremities and three upper extrem-
ities were treated. In four patients (1, 3, 5, and 24), the
contralateral leg with mild ischemia Rutherford scale <3
was not injected. Patient 3 had undergone a second trans-
plantation (case 8) for a new unhealed traumatic wound
resulting from a trafﬁc accident 6 months after the healing
of a toe ulcer following successful primary cell injection.
Among three ASO patients, all had hypertension, patient
16 had coronary arterial bypass and hyperlipidemia, and
patient 14 (Fig 1, B) had a stroke.
Table I. Characteristics of 25 patients with critical limb ischemia undergoing transplantation of puriﬁed CD34þ cells
Pt
Age,
years Etiology Symptoms Previous operation Occluded level
Follow-up
duration, months
1 42 TAO Toe ulcer, rest pain None BTK 33
2 29 TAO Rest pain None SFA 28
3 34 TAO Toe ulcer, rest pain Other toes amputation SFA 28
4 54 TAO Toe ulcer, rest pain Attempted PTA SFA 24
5 41 TAO Toe ulcer, rest pain Attempted PTA Popliteal 22
6 50 TAO Foot bottom ulcer, rest
pain
None SFA 22
7 23 Arteritis, nodular
erythema
Toe ulcer, rest pain None Below the ankle 22
8 34 TAO Toe traumatic ulcer, rest
pain
Other toes amputation,
CD34þ cells injection
SFA 20
9 40 TAO Forefoot gangrene, rest
pain
Big toe amputation Popliteal and BTK 20
10 47 Arteritis, Crohn’s disease Rest pain Thrombectomy 3 times Iliac, common femoral,
SFA, and BTK
19
11 33 TAO Toe ulcer, rest pain Another toe amputation BTK 19
12 49 TAO Rest pain None Popliteal 17
13 41 TAO Rest pain Thrombectomy twice SFA 16
14 75 ASO Toe ulcer PTA, stent (occluded)
attempted re-PTA
SFA 14
15 74 ASO Rest pain PTA, stent (occluded)
attempted re-PTA
SFA 14
16 63 ASO Foot ulcer, rest pain Attempted PTA and
bypass
Iliac 13
17 49 TAO Toe ulcer, rest pain None BTK 13
18 44 Arteritis, SLE Foot ulcer, rest pain None BTK 13
19 45 Arteritis, SLE Toes and ﬁngers
gangrene, rest pain
None Below the ankle and
wrist
13
20 48 TAO Finger ulcer, rest pain None Axillary 12
21 39 TAO Toe ulcer, rest pain None BTK 12
22 35 TAO Rest pain None SFA 12
23 47 TAO Toe gangrene, rest pain None BTK 9
24 43 TAO Toe gangrene, rest pain Thrombolysis and stent
(occluded)
SFA-popliteal 6
25 31 TAO Toe gangrene, rest pain None BTK Lost
ASO, Atherosclerosis obliterans; BTK, below the knee; Pt, patient; PTA, percutaneous transluminal angioplasty; SFA, superﬁcial femoral artery; SLE, systemic
lupus erythematosus; TAO, thromboangiitis obliterans.
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smokers at enrollment. Despite repeated patient education
on the importance of quitting smoking, only ﬁve patients
achieved complete smoking cessation, and most of the
rest merely reduced their smoking from >20 cigarettes to
5 to 10 cigarettes per day. Twenty-four patients underwent
a complete protocol-guided follow-up of a mean 18 6 7
months (range, 6-33 months), and patient 25 was lost to
follow-up.
Transplantation, debridement, and toe amputation.
The mean number of CD34þ cells was 6.85 6 6.12  107
in the ﬁnal enriched product. Reports that could be
regarded as a reference to determine the optimal cell dose
for the transplantation were rare, which is the reason that
this study was designed as a pilot that tested three different
doses. However, it was difﬁcult to predict whether the target
number of cells could be isolated in each individual patient,
particularly for the medium and high dose. If the high or
medium dose were obtained, it could be adjusted to a lower
dose, but not vice versa. Therefore, the assignment of
a participant to a dose group depended on the number ofpuriﬁed cells that were obtained. Ultimately, ﬁve patients
received a low dose, 11 received a medium dose, and nine
received a high dose. In patient 19, the cells were injected
only in both hands and in the feet because the occlusion
was below the ankle and wrist (Fig 2). In patient 7, with
a lesion below the ankle, transplantation was performed
within the foot. In the remaining patients, the cells were
injected into the calf and foot or, in patient 20, in the
forearm and hand.
Simultaneous debridement was conducted in 11
patients with infected ulcers. The individuals with ulcers
or gangrene had been treated previously by wound care
physicians and nurses for at least a few months before the
transplantation. At admission, these conditions improved;
however, it was difﬁcult to eliminate these infections in
the setting of unrelieved CLI, which was consistent with
the common situation that despite aggressive wound care,
it remains difﬁcult for CLI-induced ulcers to heal without
effective revascularization. Generally, except for coexisting
infections, amputation of a gangrenous toe was intention-
ally delayed for 2 to 4 weeks after cell transplantation,
Fig 1. A representative computed tomography angiogram shows the imaging features of thromboangiitis obliterans vs
atherosclerosis obliterans. A, In patient 9 with thromboangiitis obliterans, the occlusion was below the knee and
without calciﬁcation, whereas the iliac and femoral arteries remained unaffected. B, In patient 14 with atherosclerosis
obliterans, bilateral multilevel stenosis and occlusion are visualized from the femoral artery to the below-the-knee
arteries, and the previously placed stents at superﬁcial femoral artery were also occluded. Both patients had very
poor runoff vessels and no option for surgical or endovascular reconstruction.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 2 Dong et al 407allowing for the improvement of neovascularization and
perfusion.
Safety evaluation. Mobilization-induced events, such
as nausea, low back pain, and low-grade fever, were
observed in 10 patients and resolved spontaneously within
2 to 3 days. Numbness of the lips occurred in 13 patients
during apheresis and disappeared shortly after the oral
administration of 2 g calcium gluconate. No deaths
occurred or other morbidities developed perioperatively or
during the follow-up. No pathogenic angiogenesis in the
retina was observed at 1, 3, and 6 months.
Efﬁcacy assessment. Among the 24 patients with rest
pain who depended on narcotic analgesics before trans-
plantation, the pain was apparently relieved and the pain
medications were completely stopped in 19 patients #1
month after transplantation. The mean time to pain relief
was 3 6 1 weeks (range, 2-8 weeks). The WFPRSSsigniﬁcantly decreased from 7 6 2 to 3 6 3 at 1 month
(P < .001) and to 1 6 2 (P < .001) at 2 months, and there
was also a signiﬁcant difference between postoperative
months 1 and 2 (P ¼ .02). Twelve patients were eligible
for the PPFWT test, which increased remarkably from
4 6 3 to 13 6 7 minutes (P < .001) at 3 months and to
18 6 6 minutes (P < .001) at 6 months. There was also
a marked improvement from postoperative months 3 to
6, although the comparison was not statistically signiﬁcant
(P ¼ .07). The ABI was elevated considerably, from
0.46 6 0.21 to 0.60 6 0.17 (P ¼ .003) at 3 months
and to 0.67 6 0.15 (P ¼ .001) at 6 months, but the differ-
ence between postoperative months 3 and 6 was not statis-
tically signiﬁcant (P ¼ .19). TcPO2 was signiﬁcantly
improved from 27 6 10 to 41 6 11 mm Hg (P < .001)
at 3 months and to 55 6 12 mm Hg (P < .001) at 6
months. The improvement from months 3 to 6 was
Fig 2. A-F, Patient 19 had focal gangrene, cyanosis, and apparent hypotrophic skin changes present in the hands and
feet. The left foot had a concurrent infection. At 1 month after transplantation, (G) the granulation tissue appeared
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Table II. Comparison between baseline measurements
and interval changes
Variable WFPRSS
PPFWT,
minutes ABI
TcPo2,
mm Hg
Baseline 7 6 2 4 6 3 0.46 6 0.21 27 6 10
At 1 and 3 months 3 6 3 13 6 7 0.60 6 0.17 41 6 11
At 2 and 6 months 1 6 2 18 6 6 0.67 6 0.15 55 6 12
P P P P
1 and 3 months vs baseline <.0001 .0005 .003 .0001
2 and 6 months vs baseline <.0001 <.0001 .001 <.0001
2 and 6 months vs 1 to
3 months
.02 .07 .19 .0001
ABI, ankle-brachial index; PPFWT, peak pain-free walking time; TcPo2,
transcutaneous partial oxygen pressure; WFPRSC, Wong-Baker FACES
pain rating scale score.
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patients with ulcers, the duration of ulceration before
transplantation was 3.5 6 2.0 months, and the ulcers
healed within 5 6 4 months (range, 2-14 months) in 10
patients (74%). In four patients with unhealed ulcers, two
ASO patients (patients 14 and 16) underwent an above-
knee amputation #3 months after transplantation, and
the other two patients were still receiving wound care:
patient 6 had an ulcer on the bottom of the foot, where the
pressure is loaded, and patient 18 had extensive ulcers with
calcaneus exposure. Of the ﬁve patients with gangrene,
patient 25 was lost to follow-up and four patients under-
went toe amputations, among whom the wound healed in
patients 19, 23, and 24 within 3 6 1 months (range, 3-4
months) but did not heal patient 9, who had a below-knee
amputation 1 month after the transplantation. Patient 15,
another ASO patient, underwent an above-knee amputa-
tion at 1 month because of the progressive rest pain. The
Kaplan-Meier estimate of the rate of the freedom from
a major amputation at 6 months was 84% (95% CI, 63%-
94%).
In patients 1, 3, 5, and 24, with a mildly ischemic
contralateral leg that did not receive a cell injection, at
the time they ﬁnished the PPFWT test at 3 or 6 months,
claudication was induced in the contralateral leg, whereas
the treated side remained asymptomatic (patients 1, 5,
24) or merely had equivalent claudication (patient 3). As
for the comparison among the three different dosage
groups, the treatment outcomes showed no signiﬁcanthealthy on the toe amputation wound, (H) the cyanosis w
improved. At 3 months, (J) the amputation wound on the left
at the tip of the fourth toe on the right foot was resolved, a
contracted. At 6 months, (N) the hypotrophic skin impairm
were almost recovered to normal, except for (P) the gangren
before resolution. At 12 months, (Q and R) the feet and
gangrenous tips of the third and fourth ﬁngers of the left han
toe before transplantation, (U) amputation of its distal segm
perfusion improvement at 4 weeks after transplantation, anddifferences, except that the WFPRSS improvement at 1
month from the baseline in the high-dose group (6.3 6
1.7), which was signiﬁcantly superior to that in the low-
dose (3.2 6 3.3; P ¼ .0487) and medium-dose (3.7 6
2.8; P ¼ .0352) groups.
DISCUSSION
Since initially addressed by Isner et al18 in 1999, ther-
apeutic angiogenesis and vasculogenesis have been consid-
ered a potential alternative for the management of CLI
patients who would be unsuitable for or have poor long-
term revascularization after surgical bypass or endo-
vascular intervention, clinically achieved by gene or cell
therapy.10-13,19-21 Investigators initially preferred BM-
MNCs for cell therapy because the number of CD34þ
cells, which include endothelial progenitor cells (EPCs),
was w500-fold higher in BM-MNCs than in PB-
MNCs.4,5 However, some disadvantages of BM-MNCs
transplantation, such as requiring an w500-mL aspiration
of BM and general anesthesia, prompted investigators to
seek new approaches to obtain target cells. With the appli-
cation of G-CSF for mobilization, the number of CD34þ
cells acquired from PB-MNCs was dramatically elevated
and close to that collected from BM, thus promoting the
use of G-CSF-mobilized PB-MNCs transplantation.9,22 It
is well recognized that EPCs play a predominant role in
cell-induced neovascularization,14,15 which is why the clin-
ical trials using BM-MNCs or PB-MNCs have tested the
number of CD34þ cells as one of the main elements for
quality control.5,6,9 CD34 was deemed a common surface
marker of EPCs, hematopoietic stem cells, and mature
endothelial cells, whereas the hematopoietic stem cells
could differentiate into EPCs in the setting of
ischemia.23,24 Hence, it occurred to us that we might
isolate CD34þ cells as an alternative for transplantation.
Compared with BM-MNCs and PB-MNCs, the
implanted product of the puriﬁed CD34þ cells contained
much less erythrocytes, leukocytes, and thrombocytes;
therefore, the inﬂammatory effects of these cells, which
could possibly aggravate existing infection, might be
avoided. In addition, in this manner, whether the injection
of CD34þ cells alone would be competent for ischemia
relief could be clinically evaluated. A clinical study in this
regard was lacking until Kawamoto et al25 presented the ﬁrst
report in August 2009, in which 17 patients were treated
with cell doses of 105/kg (six patients), 5  105/kg
(eight patients), and 106/kg (three patients) and monitoredas alleviated, and (I) the trophic status of the skin was
foot was completely healed, (K) the gangrenous portion
nd (L and M) the gangrenous tips of both hands were
ent was totally reversed, and (O) the feet and the hands
ous tips of the third and fourth ﬁngers of the left hand
hands had entirely returned to normal, and (S) the
d were resolved. Patient 23 had (T) gangrene of the big
ent with osteomyelitis was intentionally delayed until the
(V) the wound was completely healed after 4 months.
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and ulcer sizes were improved in all 17 patients, but there
was no signiﬁcant difference among the three groups, similar
to the outcomes of the current study.25
In the present series, the mean time to rest pain relief
was 3 weeks, consistent with the ﬁndings in the experi-
mental study.14 The longest time to alleviation of the rest
pain reached 8 weeks in patient 24, which was likely due
to his progressive ischemia after the early occlusion of the
previous stenting impaired the pre-existing collateral perfu-
sion. He requested a below-knee amputation for the
unbearable pain 1 month after the transplantation, but
we persuaded him to wait another month. The pain was
gradually relieved at 8 weeks, and the pain-free walking
distance of the treated leg exceeded that of the contralat-
eral leg at 4 months, implying that the duration required
for the perfusion improvement may be directly propor-
tional to the severity of the ischemia. Therefore, it would
be reasonable and worthwhile to wait for a longer time in
patients with more critical ischemia.
All three patients with ASO had unsatisfactory results,
implying that puriﬁed CD34þ cells transplantation might
be less effective in patients with ASO than in those with
TAO or arteritis. A similar ﬁnding had been reported after
transplantation of BM-MNCs or PB-MNCs, and the over-
all efﬁcacy rate was 50% in ASO patients and 80% in TAO
patients.3,6,7,9 The estimated causes were that (1) the
factors causing endothelial dysfunction or depletion were
much more common in ASO patients, such as aging, dia-
betes, and hypercholesterolemia and that (2) the plasma
level of the angiogenic cytokines was attenuated in older
patients, such as vascular endothelial growth factor, which
is one of the most crucial factors in vasculogenesis and
angiogenesis.16,26-29
Three TAO patients had relatively poorer results.
Patient 9 underwent a below-knee amputation, and the
ulcers remained unhealed in patients 6 and 18. In patient
6, who was a farmer and needed to stand for long hours
during daily work, the ulcer was located on the bottom
of the foot, and the persistent pressure possibly contributed
to its disunion. Patients 9 (Fig 1, A) and 18 were the two
most severely ischemic individuals in this series, having pre-
sented with forefoot gangrene and extensive ulcers with
calcaneus exposure, respectively. In addition, the PPFWT
had a relatively limited elevation from 2 minutes preopera-
tively to 3 minutes at 3 months and 10 minutes at 6
months postoperatively in patient 10, who had an
extremely extensive occlusion involving the common and
external iliac, common and superﬁcial femoral, and
below-the-knee arteries.
The current procedures of bypass or endovascular
interventions differ from cell therapy in their manner,
time, and magnitude of perfusion restoration. Bypass and
endovascular procedures reconstruct the blood ﬂow by
directly reperfusing the native arteries, which are much
larger in diameter than the new microvessels induced by
cell therapy; thus, the perfusion can be improved more
quickly at a higher magnitude. The latter, however, hasits effect through the formation of new microvessels, which
requires a longer time and generates a lower magnitude
improvement of perfusion. Therefore, it would be more
challenging for cell therapy to reverse more acute, diffuse,
and critical ischemia, such as the three patients mentioned.
However, cell therapy showed an outstanding advantage
over conventional procedures in patients with distal
ischemia frequently caused by TAO and collagen diseases,
who were usually younger and ineligible for bypass or intra-
luminal treatments. Moreover, limb salvage, long walking
distance, freedom from physical impediment for labor,
and a higher quality of life in these younger patients could
be more meaningful to them than to elderly patients. It
would be helpful to consider these facts during patient
selection and outcome prediction during the clinical use
of cell therapy.
The current study has some limitations. TAO can only
truly be diagnosed on the basis of a pathologic examination
through a biopsy specimen or amputation, which was not
possible to perform in our patients. Many of the patients
had lesions at the iliac and femoral arteries, raising the ques-
tion of whether they had signiﬁcant early atherosclerosis
despite the absence of most risk factors of ASO. Therefore,
sufﬁcient evidence to diagnose TAO was lacking in these
patients. Similarly, ideal evidence for the diagnosis of arter-
itis includes a pathologic examination. In the four patients
with arteritis, however, only patient 7 had undergone
a biopsy in another hospital before the diagnosis of nodular
erythema, whereas the other three patients were diagnosed
mainly on the basis of clinical manifestations by rheumatol-
ogists. In addition, in the present study, there was no
control group, the total number of patients was relatively
small, and the patients had a heterogeneous etiology.
CONCLUSIONS
The transplantation of puriﬁed CD34þ cells appears to
be feasible and safe and showed encouraging outcomes in
the treatment of CLI patients who were considered unlikely
to have successful long-term revascularization with open
bypass or endovascular methods, particularly in younger
patients with TAO or collagen diseases. It would be reason-
able to conduct a prospective, randomized, placebo-
controlled trial using a more homogenous group of patients
to evaluate an optimal dose and the long-term results.
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Supplementary Fig 1 (online only). Case #1: distal below-the-knee occlusion.
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Supplementary Fig 2 (online only). Case #10: extensive occlusion the iliac, common femoral, superﬁcial, and below-
the-knee arteries.
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Supplementary Fig 3 (online only). Case #16: extreme calciﬁcation at aorta, iliac, and whole length of common
femoral arteries. Both endovascular intervention and surgical bypass technically failed.
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